Neon Therapeutics (NASDAQ:NTGN) Stock Price Up 6.4%

Share on StockTwits

Neon Therapeutics Inc (NASDAQ:NTGN)’s share price shot up 6.4% during trading on Friday . The stock traded as high as $1.01 and last traded at $1.00, 194,655 shares changed hands during trading. A decline of 30% from the average session volume of 277,613 shares. The stock had previously closed at $0.94.

Several brokerages recently weighed in on NTGN. Morgan Stanley cut Neon Therapeutics from an “overweight” rating to a “sell” rating in a research report on Tuesday, November 26th. Mizuho lowered their price objective on Neon Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. HC Wainwright cut shares of Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 27th. Zacks Investment Research lowered shares of Neon Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 29th. Finally, Bank of America cut shares of Neon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. Neon Therapeutics presently has an average rating of “Hold” and a consensus price target of $10.58.

The firm’s 50 day moving average price is $1.70 and its 200-day moving average price is $3.02. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.59 and a current ratio of 4.59.

Neon Therapeutics (NASDAQ:NTGN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.04). As a group, research analysts predict that Neon Therapeutics Inc will post -2.54 earnings per share for the current year.

In other Neon Therapeutics news, insider Richard Gaynor sold 22,322 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $1.24, for a total transaction of $27,679.28. Following the transaction, the insider now owns 201,822 shares in the company, valued at $250,259.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 38.93% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in NTGN. BlackRock Inc. increased its holdings in Neon Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock worth $3,631,000 after acquiring an additional 79,729 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Neon Therapeutics by 3.6% during the second quarter. Vanguard Group Inc. now owns 612,398 shares of the company’s stock valued at $2,903,000 after purchasing an additional 21,387 shares in the last quarter. State Street Corp lifted its holdings in Neon Therapeutics by 14.7% during the third quarter. State Street Corp now owns 221,268 shares of the company’s stock valued at $381,000 after purchasing an additional 28,334 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Neon Therapeutics in the third quarter valued at about $361,000. Finally, Northern Trust Corp grew its position in shares of Neon Therapeutics by 8.5% in the second quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock valued at $789,000 after purchasing an additional 12,971 shares during the period. 58.19% of the stock is currently owned by hedge funds and other institutional investors.

Neon Therapeutics Company Profile (NASDAQ:NTGN)

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Article: How can investors benefit from after-hours trading?

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.